RPRX

Royalty Pharma plc

RPRX · CIK 1802768 · Annual (10-K) · Last 6 years

Financial Trends

Revenue$2.4B
20202025
Net Income$0.8B
20202025
Operating CF$2.5B
20202025
Free Cash Flow
20202025

Income Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue$2.4B$2.3B$2.4B$2.2B$2.3B$2.1B
Cost of Revenue
Gross Profit
R&D Expense$0.5B$0.0B$0.1B$0.2B$0.2B$0.0B
SG&A Expense
Operating Income$1.6B$1.3B$1.5B$0.3B$1.4B$1.6B
Net Income$0.8B$0.9B$1.1B$0.0B$0.6B$1.0B
EPS (Basic)$1.79$1.92$2.54$0.10$1.49$1.32
EPS (Diluted)$1.78$1.91$2.53$0.10$1.49$1.32

Balance Sheet

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Total Assets$19.6B$18.2B$16.4B$16.8B$17.5B$16.0B
Current Assets$1.5B$1.8B$1.3B$2.6B$2.9B$2.7B
Cash & Equivalents$0.6B$0.9B$0.5B$1.7B$1.5B$1.0B
Total Liabilities$9.9B$7.9B$6.3B$7.3B$7.3B$6.1B
Current Liabilities$0.6B$1.3B$0.2B$1.2B$0.2B$0.3B
Stockholders' Equity

Cash Flow Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Operating Cash Flow$2.5B$2.8B$3.0B$2.1B$2.0B$2.0B
Investing Cash Flow$-1.6B$-2.7B$-2.1B$-1.0B$-1.9B$-2.8B
Capital Expenditures
Financing Cash Flow$-1.2B$0.4B$-2.1B$-0.9B$0.4B$1.5B